ReviewDrugs2015
Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial.BMC medicine · 2026Trial
- Nanoparticle-Based Drug Delivery Systems: Current Advances and Future Directions.Current drug targets · 2026Review
- Spectroscopic and molecular docking studies on binding interactions of camptothecin drugs with bovine serum albumin.Scientific reports · 2025Article
- Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity.BioImpacts : BI · 2025Review
- Novel progressive deep learning algorithm for uncovering multiple single nucleotide polymorphism interactions to predict paclitaxel clearance in patients with nonsmall cell lung cancer.Cancer innovation · 2024Article
- Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer.Journal of cancer research and clinical oncology · 2024Article
- Interplay between paclitaxel, gap junctions, and kinases: unraveling mechanisms of action and resistance in cancer therapy.Molecular biology reports · 2024Review
- Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics.Beilstein journal of nanotechnology · 2024Article
- Targeting Glucose Metabolism in Cancer Cells as an Approach to Overcoming Drug Resistance.Pharmaceutics · 2023Review
- Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment.Nature communications · 2023Article
- Article
- Functionalized Carbon Nanoparticles as Theranostic Agents and Their Future Clinical Utility in Oncology.Bioengineering (Basel, Switzerland) · 2023Review
- FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance.Frontiers in oncology · 2023Article
- Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.BMC cancer · 2022Article
- Adenosquamous Carcinoma of Skene's Gland: A Case Report and Literature Review.Frontiers in oncology · 2022Article
- Differences in Fatty Acid Oxidation betweenACS omega · 2021Article
- Article
- Theranostic applications of stimulus-responsive systems based on carbon dots.International journal of polymeric materials · 2021Article
- The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.Frontiers in oncology · 2021Review
- How Different Albumin-Binders Drive Probe Distribution of Fluorescent RGD Mimetics.Frontiers in chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticle albumin-bound paclitaxel (Abraxane) [hereafter referred to as nab-paclitaxel] is a taxane developed to avoid some of the toxicities associated with solvent-bound (sb) paclitaxel. Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. This article summarizes pharmacological, efficacy and tolerability data relevant to the use of nab-paclitaxel in this indication. Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. The nab-paclitaxel regimen also provided benefit over the sb-paclitaxel regimen in certain patient subgroups, including patients with squamous cell histology (in terms of ORR) and patients who were elderly (in terms of OS). Nab-paclitaxel plus carboplatin had a manageable tolerability profile with some benefits over sb-paclitaxel plus carboplatin, including lower rates of grade ≥3 neutropenia, peripheral neuropathy, arthralgia and myalgia, although was associated with more grade ≥3 anaemia and thrombocytopenia. Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.